相关实验视频

Updated: Jan 18, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

重新定义白蛋白-白素得分:预测建模和多维整合肝脏和全身疾病中的多维整合

Berkay Demirors¹, Ramin Shekouhi², Paola Berrios Jimenez³

¹Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, United States. demirorsb2@upmc.edu.

World journal of gastroenterology

|September 12, 2025

概括

专 - 胆红素 (ALBI) 评分为评估非恶性肝脏疾病的肝功能和预后提供了一个简单而有效的工具. 它的应用正在扩展到癌症之外,在指导各种肝脏疾病的临床决策方面显示出希望.

科学领域:

肝病学肝病学是一种肝病学.
临床医学临床医学
生物标志物研究生物标志物研究

背景情况:

传统的肝功能评分,如Child-Pugh和MELD,在区分具有类似预后的患者方面存在局限性.
专白素 (ALBI) 评分越来越多地被认为是其在肝脏疾病评估中的作用.
现有的研究主要集中在ALBI在肝细胞癌中的实用性.

研究的目的:

在非恶性肝脏疾病中分析白蛋白-白素 (ALBI) 评分的预后作用.
将ALBI与 Child-Pugh 和 MELD 等已有的评分系统进行比较.
审查支持ALBI临床实用性的最新证据,并指导未来的研究.

主要方法:

对评估白蛋白-白素 (ALBI) 评分的最近研究的综述.
对ALBI与Child-Pugh和MELD分数进行比较分析.
对ALBI的组件和分级系统进行了深入分析.

主要成果:

在其他分期系统下,ALBI得分显示出在区分具有类似预后的患者的潜力.
在包括非恶性疾病在内的各种肝脏疾病中,ALBI与生存,复发和并发症具有积极的相关性.
有证据表明,ALBI可以预测接受不同治疗方式的患者的结果,毒性和并发症.

结论:

专 - 胆氨酸 (ALBI) 评分显示,在评估非恶性肝脏疾病中的肝功能和预后方面有显著的前景.
需要进一步的大规模前性研究来验证ALBI在常规临床实践中的整合.
ALBI可能在指导治疗计划和预后方面发挥关键作用,用于更广泛的肝脏疾病.

关键词:

专蛋白 - 胆氨基分数得分肝功能评估评估肝功能评估肝脏移植肝脏移植非恶性肝病的非恶性肝病.非侵入性的生物标志物主要胆道胆管炎是一种胆道胆管炎.预测模型的预测模型.

更多相关视频

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

相关概念视频

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...

Diseases of the Liver and Gallbladder

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...